Kornimate/medical-research-clean huggingface dataset:
evaluation of glycemic control and quality of life in adults with type 1 diabetes during continuous glucose monitoring when switching to insulin glargine 300 u/ml

Conditions: Type 1 Diabetes

Summary: retrospective multicenter study analyzing data gathered during the future study (s59342) to assess the effect of using insulin glargine 300 u/ml (gla-300) on measures of diabetes control and quality of life. of the future participants, data about the type of insulin the participants used will be gathered. on the basis of these data participants will be divided in two groups (control or investigational). change in glycemic control and quality of life from before to after the switch to gla-300 (investigational group) will be compared to the change of glycemic control and quality of life of the future participants who did not switch to gla-300 (control group). the future study was a 24-month during multicenter observational cohort study analyzing data on the use of the abbott freestyle libre in people with diabetes. data were gathered during standard clinical follow-up, and from questionnaires that were presented to the participants at defined time points.


Eligibility criteria:
1. investigational group inclusion criteria: * participant in the future study * diagnosed with type 1 diabetes ≥3 months before start of the future study * use of insulin pens for the entirety of the future study * used insulin detemir (levemir®), insulin glargine 100 u/ml (lantus®) or an equivalent as basal insulin before switch to gla-300 (toujeo®) * switched to gla-300 (toujeo®) during the future study for a sufficient amount of time (at least two consecutive diabetes consultations = 8 months) exclusion criteria: * use of fast-acting insulin aspart (fiasp®) before or after switch to gla-300 * not using bolus insulin (only basal insulin) * for women: pregnant or planning pregnancy during the future study 2. control group inclusion criteria: * participant in the future study for at least 18 months * diagnosed with type 1 diabetes ≥3 months before start of the future study * use of insulin pens for the entirety of the future study * use insulin detemir (levemir®), insulin glargine 100 u/ml (lantus®) or an equivalent as basal insulin during the entirety of the future study exclusion criteria: * use of fast-acting insulin aspart (fiasp®) * not using bolus insulin (only basal insulin) * for women: pregnant or planning pregnancy during the future study * switch to gla-300 (toujeo®) or insulin degludec (tresiba®) before 18 months in future study (if switched after 18 months, only data up to switch to gla-300 \[toujeo®\] or insulin degludec \[tresiba®\] will be used for this control participant)

Keywords: insulin glargine 300 u/ml continuous glucose monitoring
a culinary-based intensive lifestyle program for patients with obesity

Conditions: Obesity

Summary: the study team proposes in this pilot to test, in a single-arm mixed-methods study, the feasibility, acceptability, and preliminary effectiveness of the 16 modular classes taught by a chef, dietitian, and health coach. while the pilot may not have the power to detect significant change, it will provide preliminary data for a nih application to further test this curriculum in a pragmatic, community-based, randomized multi-site teaching kitchen collaborative curriculum (tkcc) study planned for jan 2022 or thereafter. if effective, the tkcc has potential to impact population health through translation into teaching kitchens nationally and adaptation to clinic /community settings.


Eligibility criteria:
inclusion criteria: * community-dwelling * english speaking patients * aged 30-65 (in order to capture adults living independently) * diagnosis of class i or ii obesity (bmi 30-39.9 kg/m2) * participants must be available for and willing to commit to the sixteen classes either in person or virtually. * must have a device with a camera (smartphone, tablet, computer) * use email and text * home wi-fi with high-speed internet * must have minimal cooktop and oven capacity at home * participants will be referred and have medical clearance from a primary care provider at dartmouth-hitchcock exclusion criteria: * patients taking obesity or diabetes medications as assessed by study medical director * severe obesity (bmi≥40kg/m2) * diagnosis of type 2 diabetes (ha1c ≥ 6.5) in the past (excluding gestational diabetes) * implanted electronic medical device * history of bariatric surgery * current participation in a longitudinal culinary or weight management program, including the d-h weight and wellness center * severe mental health or life-threatening illnesses * unstable cardiovascular disease * hospitalization for depression in past 6 month * self-report of alcohol or substance abuse within the past 12 months * diet / exercise contraindications * other medical, psychiatric, or behavioral limitations that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention protocols determined by pi * prisoners * pregnant women will not be eligible to participate nor will those unable or unwilling to give informed consent or communicate with local study staff.
the application of honey on perineal sutures

Conditions: Perineal Tear; Pain; Burns

Summary: evaluate the effect of honey on perineal tears or episiotomies pain associated or not with anterior vulvar tears after vaginal delivery.


Eligibility criteria:
inclusion criteria: * major women * giving birth vaginally in the maternity of geneva university hospital * first and second degree perineal tears or episiotomy * french speaking women * the day of the delivery exclusion criteria: * allergic to honey and bees * drug use * postpartum hemorrhage
laser activation in reducing pain during and after root canal treatment for painful lower molar teeth.

Conditions: Decayed Teeth

Summary: effectiveness of lasers in reducing pain during and after root canal treatment for mandibular molar teeth affected with acute irreversible pulpitis.

aim : to assess the intraoperative and postoperative pain incidence for single visit root canal treatment for mandibular molar teeth with acute irreversible pulpitis following laser activation. materials and methods: the study will account the patients who are referred to the department of endodontics,both male and female patients,with pain due to acute irreversible pulpitis from carious mandibular first and second molar teeth requiring root canal treatment. subjects of age 13 to 70 years who met the inclusion criteria and responded positively to cold test will be included in the study. single visit root canal treatment with 2.5 ml of 2% lignocaine containing 1:80,000 adrenaline for an inferior alveolar block injection will be administered for each individual. after achieving anesthesia, patients who exhibit pain following access opening will be subjected to diode laser application on the pulp canal orifices. with regard to intraoperative pain, pre laser and post laser intraoperative pain incidence will be recorded. once when the intraoperative pain incidence is reduced, patients will be reassessed for the need of additional anesthesia. if fully anesthetised, root canal procedure will be completed. preoperative, intraoperative( before and laser application) pulse rate will also be measured. the levels of preoperative and post-operative pain at 24 hrs and 48 hrs for each patient will be recorded using a 10-point visual analog scale (vas).

Eligibility criteria:
inclusion criteria: * patients with painful mandibular molar teeth due to caries with no history of medication intake before 7 days prior to root canal treatment * patients who respond exaggerated pain with or without lingering response on cold test exclusion criteria: * patients who do not have pain upon access opening following local anesthesia administration * teeth with poor periodontal or restorative prognosis, * patients with serious systemic ailments or conditions hindering single visit root canal treatment * patients not willing to participate in the post operative recall evaluation * teeth with anatomic variations and * allergic patients are excluded
respiratory function monitoring of mechanical ventilation in patients with chest blunt injury

Conditions: Lung Contusion

Summary: the goal of this observational study is to learn about eit in observing the application of lung protective ventilation strategies in patients with pulmonary contusion, particularly the impact on pulmonary ventilation blood flow ratio, oxygen, and condition. the main question it aims to answer is: can lung protective ventilation strategies improve respiratory function in patients with severe chest contusion? we will collect clinical data of participants who already taking lung protective ventilation strategies as part of their regular medical care.

trauma is the leading cause of death among middle-aged and young people in china, with over 25% of patients dying from chest trauma. the incidence of pulmonary contusion in severe chest trauma is over 70%, and it is an important cause of respiratory failure and even death in patients. the occurrence of pulmonary contusion and respiratory failure in patients with chest contusion is a dynamic process, and regional inhomogeneities of the damaged lung should be taken into consideration to develop improved ventilation strategies. currently, there is no ideal monitoring method to evaluate the severity of injury, and guide the ventilation strategies. electrical impedance tomography (eit) is a non-invasive, radiation-free imaging technique. it measures regional lung ventilation and aeration distribution by means of changes in electrical potentials at the skin surface of the chest wall during breathing cycles, which has been proven to have good practicality in patients with non-invasive ards and pulmonary embolism. in this study, we aim to characterize the physiologic effects of positive end expiratory pressure (peep) on key mechanisms of regional lung protection, namely: recruitment, reduced atelectrauma, and improved ventilation-perfusion matching, by ct scan and eit

Eligibility criteria:
inclusion criteria: * patients with severe chest contusion admitted to the intensive care unit (icu); * abbreviated injury scale (ais) ≥ 3 and/or blunt pulmonary contusion 18 score (bpc18) ≥ 3; * age range from 18 to 90 years old; * mechanical ventilation; * stay in the icu for less than 12 hours. exclusion criteria: * perinatal women; * expected to be mechanically ventilated for less than 48 h; * expected duration of stay in the icu is less than 24 hours; * there are contraindications for the use of eit (pacemaker implantation, local skin wounds after chest surgery, etc.); * accept extracorporeal membrane oxygenator; * mechanical ventilation\>7 days; * confirmed ventilator-associated pneumonia; * pneumothorax without drainage or presence of subcutaneous emphysema.

Keywords: chest contusion lung contusion electrical impedance tomography pulmonary perfusion
opiate sleep disordered breathing study

Conditions: Sleep Apnea

Summary: lay title: a study of breathing pauses during sleep in patients on long term opiates. sleep apnoea is a term which refers to frequent breathing pauses during sleep. breathing can stop at night due to the upper airway collapsing (obstructive sleep apnoea)or reduced signals from the brain driving breathing (central sleep apnoea). clinical observation has noticed that patients on opiates have an increase in sleep apnoea. hypothesis: this study looks at the relationship of opiates (when used for patients chronic pain) and the occurrence of sleep apnoea. it is expected that there will be an increase in sleep apnoea (particularly of the central variant) particularly in patients on long term opiates.

the purpose for this study is to test the hypothesis that sleep disordered breathing is more prevalent amongst a group of patients on high dose opiates for chronic pain. aims 1. to define the prevalence of sleep disordered breathing in a group of patients on oral morphine for chronic pain. 2. to determine the prevalence of respiratory failure in this cohort of patients. patients on long term opiates (\>6 months) from an outpatient pain clinic population on long acting morphine formulations \> 40 mg/day, oxycontin 30 mg/day, and methadone \> 20 mg/day were prospectively recruited. home polysomnograms were done on them. during their clinical review they have spirometry, arterial blood gases, psychomotor vigilance tests done on them.

Eligibility criteria:
inclusion criteria: * patients on long acting morphine \>40mg/day, oxycontin \>30mg/day, and methadone \>20mg/day were contacted. * stable opiate dose for 2 weeks * lives within 80km of fmc exclusion criteria: * significant ccf/cva * severe copd * major psychiatric illness * history of substance abuse in the last 3 months

Keywords: opiates sleep apnea ventilatory failure
clinical trial of pregabalin and cox2 in spinal stenosis

Conditions: Spinal Stenosis Lumbar

Summary: aim of this prospective, single-blind, randomized study was to compare the efficacy of the combination of celecoxib and pregabalin and celecoxib only monotherapy for treatment of chronic low-back pain.

the efficacy and safety of the association of celecoxib \[a selective cyclooxygenase-2 (cox-2) inhibitor\] and pregabalin (commonly used to control neuropathic pain), compared with monotherapy of each, were evaluated for the treatment of chronic low-back pain, a condition known to be due to neuropathic as well as nociceptive pain mechanisms. we will compare the efficacy of the combination of a selective cox-2 inhibitor (celecoxib) and an antineuropathic drug, pregabalin, versus celecoxib only monotherapy, in the treatment of spinal stenosis. each treatment lasted 8 weeks primary outcome is mean pain reduction following different treatments regimes. secondary outcomes are the changes of pain sensitivity, oswestry disability index, adverse effects due to the treatments under study.

Eligibility criteria:
inclusion criteria: * spinal stenosis exclusion criteria: * koval grade \>=3 * other musculoskeletal disorders which cause pain on other joint * bleeding risk or ulcer history * severe cardiovascular, pulmonary, renal, brain, liver dysfunction

Keywords: pregabalin selective cox-2 inhibitor
preventing early childhood caries with silver diamine fluoride

Conditions: Dental Caries

Summary: background: silver diamine fluoride (sdf) solution is effective in arresting early childhood caries (ecc). previous studies suggested that it might exert a preventive effect in managing ecc. however, no well-designed clinical trial has been performed to study this topic. the aim of this randomised clinical trial is to assess whether 38% sdf is superior to 5% sodium fluoride (naf) varnish in preventing new carious lesions in primary anterior teeth. methods/design: this is a phase ii single-centre randomized, double-blind, active-controlled, parallel-group pragmatic trial. the hypothesis tested is that 38% sdf is more effective than 5% naf in preventing new caries development in primary anterior teeth. approximately 2,100 three-year-old kindergarten children who are generally healthy and with parental consent will be recruited. this sample size is sufficient for an appropriate statistical analysis of superiority trial with power at 80%, allowing for a 15% drop-out rate. stratified randomization will be adopted for the intervention allocation. the intervention is either 38% sdf or 5% naf (as positive control) therapy on primary upper anterior teeth. dental examination followed by fluoride therapy will be conducted every six months until 30 months in kindergartens by a single examiner. the examiner, children and children's parents will be blinded to the treatment allocation. questionnaire survey will be conducted to study the children's oral health-related behaviours and their socioeconomic backgrounds. discussion: the effectiveness of 38% sdf in preventing ecc remains uncertain. if the results are as anticipated, it will help change the standard of care that using 5% naf for ecc prevention. in addition, the results will be widely available and increase adoption of sdf in other countries to reduce the global burden of ecc.


Eligibility criteria:
inclusion criteria: * generally healthy, with parental consents exclusion criteria: * uncooperative and difficult to manage, have major systemic diseases such as porphyria, or are on long-term medication such as anti-epileptic drugs.
health promotion for women with fibromyalgia

Conditions: Fibromyalgia

Summary: women with chronic disabling conditions such as fibromyalgia syndrome (fms) must manage a wide variety of disease-related, intrapersonal, and environmental demands to maintain their health and quality of life. engaging in health-promoting behaviors is one strategy recommended to manage disease symptoms and enhance quality of life (usdhhs, 2000). the purpose of this four-year study is to refine and test a theoretically and empirically based intervention to promote the health and well being of women with the chronic disabling condition of fibromyalgia. we hypothesize that women who participate in the "lifestyle counts" intervention will report more greater self-efficacy for health behaviors, more frequent health behaviors and more positive health and quality of life than women in the comparison group.

this wellness intervention, originally developed and tested in a randomized clinical trial of women with ms (n=113), resulted in significant improvements in self-efficacy, health behaviors and improvements in pain, social functioning, mental health and emotional role-functioning. the specific aims of this study are to examine the effects of the adapted wellness intervention on self-efficacy, resources, barriers, health behaviors and health outcomes for women with fibromyalgia. a sample of 160 women with fms will be recruited to participate in a randomized clinical study to determine the effects of this wellness intervention that includes an eight week health promotion/behavior change component and 3 months of follow-up phone support. content regarding stress management, lifestyle adjustment, physical activity, nutrition and women's health issues will be presented with an emphasis on the unique adaptations and associated skills required to empower women with the tools for exercising personal control over their health behaviors. the effects of the intervention on outcome variables will be assessed over an 8-month period with measurements at baseline, 2 months (immediately after the educational/skill-building component), 5 months (after 3 months of phone support) and at 8 months.

Eligibility criteria:
inclusion criteria: * female * physician verified diagnosis of fibromyalgia for at least 6 months, age 18 to 75, * able to speak and read english * willing to participate in 8-month intervention study exclusion criteria: * pregnancy * male * concurrent medical conditions (as judged by their physician) for which changes in diet and exercise would be contraindicated

Keywords: women fibromyalgia syndrome health behaviors quality of life
nasal decongestion and obstructive sleep apnea

Conditions: Obstructive Sleep Apnea Syndrome; Rhinitis

Summary: whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.


Eligibility criteria:
inclusion criteria: * obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index \>10/h) * chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months) exclusion criteria: * nasal surgery within the last 6 months * current treatment with nasal decongestants or topical steroids * sleep disorders other than obstructive sleep apnea * internal medical or psychiatric disorders that interfered with sleep

Keywords: sleep apnea, rhinitis
study of the relationship between sleep quality and daytime-nighttime variations of blood pressure and plasma glucose type i

Conditions: Type 1 Diabetes

Summary: the primary objectives are to compare the mean levels of the sleep quality parameters of subjects : with a nocturnal fall of the sbp (systolic blood pressure), dbp (diastolic blood pressure) and map (mean arterial pressure) over of egal to 10% (dipping subjects) and of subjects with a nocturnal fall of sbp, dbp and map inferior to 10% (non dipper subjects). the secondary objectives are : establish correlations between: * the quality of sleep parameters * the parameters of bp variations between the diurnal and nocturnal periods and the awake periods of sleep defined in reference to polysomnography. * the glycemia levels on 24h with a glycemic holter. the parameters of the sympathic system activation evaluated in reference to the measure of the baroreflex sensibility during the awake period.

it is a prospective monocentric study after a preliminary period of depistage of the sleep abnormalities by oximetry at home. the patient would be hospitalized for two consecutive days (j0, j1). and the following evaluations will be done: * nocturnal oxymetric + epworth questionnaire + clinical questionnaire to detect sleep perturbations at home. * blood pressure + heart rate measure * ambulatory blood pressure monitoring on 24 hours * polysomnographic measurements during the j0-j1 night spend at the hospital. * questionnaire of sleep quality and of quality of life. * glycemic measurements on 24h (j0-j1). * measure of the baroreflex sensibility during the awake period at j1. * electrocardiogram * biological examinations (blood and urinary).

Eligibility criteria:
inclusion criteria: * male and female patients between 18 and 60 years of age * who have given their written consent to participate in this study * who are affiliated to the french social security system * are able to travel to grenoble university hospital * type i diabetes in reference to the 1997 criteria (american diabetes association) without any recent cetoacidosis or severe hypoglycaemia during the previous month and with a hba1c \< 10% during the previous month. * normal blood pressure or essential hypertension light or moderate (sbp) at rest in the sitting position \>= 140 mmhg and \ = 90 mmhg et \< 110 mmhg), with or without treatment. exclusion criteria: * non stabilised diabetes with at least one episode of acidoketosis decompensation or hypoglycemic coma during the previous month. * diabetic nephropathy patent stage 4 with a creatinine \> 150 mol / l and / or creatinine clearance \<50 ml / min * diabetic nephropathy in evolution * severe hypertension (sbp at rest in the sitting position \>= 180 mmhg and/or dbp \>= 110 mmhg)

Keywords: diapasom sleep quality type i diabete blood pressure plasma glucose daytime and nighttime variations